OasisLMS

Despite the wide recognition of obesity as a chronic disease, the clinical recommendations that guide the diagnosis of obesity and its management have not been aligned sufficiently with the clinical processes normally adopted for other chronic diseases. To stimulate the development and implementation of clinical guidelines for obesity more aligned with those already in place for other chronic diseases, the European Association for the Study of Obesity (EASO) proposed a new framework for the diagnosis, staging and management of obesity in adults.

1. After participating in the webinar, learners will be able to discuss the appropriate individual therapeutic targets with patients and adapt the choice of the modalities of intervention according to the probability of achieving the targets.

2. After this webinar, learners will be able to perform a diagnostic work-up and staging of obesity not based solely on the presence of an abnormal and/or excessive fat accumulation (anthropometric component), but including a careful analysis of the present and potential effects that dysfunctional and/or excessive fat accumulation may have on health (clinical component).

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACCME Activity ID 202573221

Date of Release: October 1, 2024
Date of Termination: December 31, 2026

No commercial support was received for this activity.

Luca Busetto, MD, PhD: Advisor relationship with Boehringer Ingelheim (Pharmaceuticals), Bruno Farmaceutici (Pharmaceuticals), Eli Lilly (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), and Pfizer (Pharmaceuticals). Speaker relationship with PronoKal (Supplement) and Rhythm (Pharmaceuticals).

Monica Agarwal, MD: No Relevant Financial Relationships

Johnny Figueroa, PhD: No Relevant Financial Relationships

Leslie Golden, MD, MPH: No Relevant Financial Relationships

Valentina Ivezaj, PhD: No Relevant Financial Relationships

Aaron Kelly, PhD: No Relevant Financial Relationships

Robert Kushner, MD: Advisor Relationship with Novo Nordisk (Pharmaceuticals), WW (Medical Food), and Eli Lilly (Pharmaceuticals) Consultant relationship with Altimmune (Pharmaceuticals), Pfizer Inc. (Pharmaceuticals), and Boehringer Ingelheim (Pharmaceuticals)

Magdalena Pasarica, MD, PhD: No Relevant Financial Relationships Jonathan Purnell, MD Consultation Relationship with Novo Nordisk (Pharmaceuticals), Boehringer Ingelheim (Pharmaceuticals), and Luciole (Pharmaceuticals)

Amanda Velazquez, MD: Advisor relationship with WW (Medical Food) Consultation Relationship with Novo Nordisk (Pharmaceuticals)

Denise Wilfley, PhD: No Relevant Financial Relationships

No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee.

1. Busetto L, Dicker D, Frühbeck G, Halford JCG, Sbraccia P, Yumuk V, Goossens GH. A new framework for the diagnosis, staging and management of obesity in adults. Nat Med. 2024 Jul 5. doi: 10.1038/s41591-024-03095-3. PMID: 38969880.

2. Busetto L, Sbraccia P, Vettor R. Obesity management: at the forefront against disease stigma and therapeutic inertia. Eat Weight Disord. 2022 Mar;27(2):761-768. doi: 10.1007/s40519-021-01217-1. Epub 2021 May 29. PMID: 34052990; PMCID: PMC8933346.